01 The hemodialysis market is increasingly shifting toward home-based care, supported by policy changes and advances in dialysis technology. In the U.S., CMS expanded Medicare payment for home dialysis for eligible patients with acute kidney injury (AKI) in 2025, giving patients more treatment flexibility. CMS also updated guidance in 2025 for preconfigured hemodialysis systems designed for both home and in-center use, highlighting the growing role of simplified equipment. However, in-center treatment remains dominant: CMS data show that about 83% of dialysis patients were receiving in-center hemodialysis, while home hemodialysis accounted for roughly 4% in recent reporting years. Rising kidney disease prevalence is another major demand driver, with the CDC estimating that 14% of U.S. adults, or around 37 million people, had chronic kidney disease in 2026. These trends point toward greater adoption of home dialysis, connected devices, and patient-centered treatment models.
November 2025 Lord's Mark Industries acquired an 85% stake in Renalyx Health Systems, bringing India's indigenous AI- and cloud-enabled smart hemodialysis technology into its portfolio and establishing Renalyx as its R&D arm for advanced renal care devices.
August 2025 AdventHealth Manchester launched a new 24/7 inpatient hemodialysis program, expanding access to dialysis services and strengthening renal care infrastructure for hospitalized patients.
March 2025 The U.S. FDA announced that shortages of hemodialysis bloodlines would continue through early fall 2025 and collaborated with manufacturers and dialysis providers to mitigate supply disruptions affecting hemodialysis treatment.